KARD.US Kardigan, Inc. Common Stock

Healthcare Biotechnology USA Stocks
13.82 USD
Close of Nov 15, 2026
12.23 27.00
Market cap
USD 1.29B
P/E
-
P/B
2.10x
ROE
-53.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is KARD.US undervalued?

Graham number

The Graham number of Kardigan, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kardigan, Inc. Common Stock fundamental analysis

No fundamental analysis for Kardigan, Inc. Common Stock yet.

Kardigan, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kardigan, Inc. Common Stock

Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimi…

Full company profile